Ripple taps Tunstall for personal safety service
NEW YORK and FORT LAUDERDALE, Fla. – Ripple Network Technologies has launched a kickstarter campaign for a personal safety device and service that would give users nationwide access to connected health leader Tunstall’s monitoring team. “Whether walking alone at night, meeting somebody new for the first time, facing immediate danger, or even traveling the country, Ripple’s device and service, utilizing Tunstall’s state-of-the-art response center, can keep you one click away from the help you need,” said Casey Pittock, president and CEO of Tunstall Americas, in a statement. Ripple users can discreetly signal their monitoring team for help with the click of a penny-sized Bluetooth wearable, and the monitoring team can dispatch emergency services if the user needs it.
Propeller teams with Novartis for COPD platform add-on
MADISON, Wis. – Digital health company Propeller Health has partnered with Novartis Pharma to develop an add-on sensor for the Breezhaler inhaler, which is used for Novartis’ portfolio of COPD treatments. “The addition of this major respiratory franchise represents an important next step in our mission to bring valuable digital companions to everyone’s respiratory treatments,” said David Van Sickle, CEO of Propeller Health, in a statement. As patients use the Breezhaler, a capsule-based dry powder inhaler, the new custom sensors will allow for passively recording and transmitting compliance data. “With data from these medication sensors and interfaces, Propeller strengthens the relationships between patients and their physicians and helps them build effective treatment programs together,” Van Sickle said. The Novartis-Propeller partnership is focused on COPD in Europe, and adds to other Propeller-pharma partnerships announced earlier.
VivaLnk launches Vital Scout wearable patch
SANTA CLARA, Calif. – Wearable telehealth device company VivaLnk has launched Vital Scout, a Band-Aid-sized wearable patch that allows users to monitor their physical and mental health. “Whether an individual has a high-stress job, a health issue he wants to monitor, or he’s just being proactive, Vital Scout provides a true, real-time assessment of stress levels, sleep, exercise and recovery—letting consumers take charge of their health,” said Jiang Li, CEO of VivaLnk, in a statement. Vital Scout is made with the company’s eSkin technology, and is a flexible, breathable electronic circuit that uses multiple sensors to continuously monitor critical body functions like heart rate and heart variability, respiration rate, stress levels and stress recovery, sleep status and activity/training, transmitting the information to the user’s smartphone or tablet via Bluetooth. Users can set alerts on the Vital Scout app to notify them when stress levels are high so they can take action to improve their health. The patch is attached on the chest with medical-grade adhesives, and can be worn for 72 hours before recharging the battery.
Ascensia, Glooko partner for diabetes management solutions
BASEL, Switzerland, and MOUNTAIN VIEW, Calif. – Ascensia Diabetes Care and Glooko Inc. have partnered to bring together their state-of-the-art diabetes management solutions and improve diabetes data management and analytics. The collaboration includes integrating Glooko’s Diabetes Data Management Platform with Ascensia’s Countour Next One and Contour Plus One blood glucose monitoring systems. “By linking our systems to Glooko’s Diabetes Data Management Platform, we want to enable better understanding and analysis of diabetes data, and ultimately help improve the lives of people with diabetes,” said Michael Kloss, CEO of Ascensia Diabetes Care, in a statement. The integration of the solutions will allow blood glucose data to be accessed by Glooko’s mobile app and Clinic Data Upload products directly from the Contour meters via Bluetooth and through an automatic feed through the Contour Cloud. People with diabetes will be able to view their data through both companies’ mobile apps, and health care professionals will be able to seamlessly access data from the two Ascensia systems that fits into their workflow through the Glooko Clinic Solution. The global agreement covers all markets where Glooko and these Ascensia systems are available, and the integration is expected to be available later this year.
FDA clears cardiac mapping system
DUBLIN, Ireland – Medtronic has received U.S. Food & Drug Administration clearance for the CardioInsight Noninvasive 3D Mapping System, which was first used in the U.S. commercially at the Mount Sinai Hospital this month.
“The CardioInsight system further expands the portfolio of solutions available for common and complex arrhythmias,” said Colleen Fowler, vice president and general manager of the Medtronic AF Solutions business, created when Medtronic acquired CardioInsight in 2015.
Cardiac mapping is typically accomplished by inserting a catheter into the heart through an artery or vein. It allows physicians to locate the origin of a patient’s irregular heart rhythms.
The CardioInsight system uses a 252-electrode sensor vest that is worn by the patient to pair body surface electrical data with heart-torso anatomy. The technology creates 3D electroanatomic maps of the heart by collecting electrocardiogram signals from the chest, and combining those signals with data from a computed tomography scan of the heart.
The vest technology contours to the patient’s body and allows for continuous and simultaneous panoramic mapping of both atria or both ventricles, which cannot be achieved with current invasive methods.
“By offering this noninvasive approach, we are effectively streamlining the clinical procedure planning process for clinicians, making it easy for patients to receive precise mapping results from their providers right at their bedside,” said Dr. Vivek Reddy, director of cardiac services at Mount Sinai Hospital and the Mount Sinai Health System, who was the first to use the system in the U.S.